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has been estimated from clinical trials data. The cost of general practitioner visits,
specialist visits, hospitalizations and emergency department visits were included.
Costs and utility values attached to various health states were taken from the
published literature. RESULTS: Lacosamide adjunctive therapy was associated
with 6,730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs),
compared to the standard therapy armwithin the two-year timeframe. Treatment
with lacosamide was associated with a cost of $223 per seizure avoided, and
$39,574 per QALY gained versus standard therapy over two years and falls within
acceptable thresholds of cost-effectiveness in the United States. Results calculated
for 6-, 12- and 18-month follow-up showed respective incremental cost-utility ra-
tios of $55,465, $46,587 and $44,559 and cost per seizure avoided of $733, $305 and
$260. Using a willingness-to-pay threshold of $50,000 per QALY, 77% of the simu-
lations fell below this value after 2 years of treatment. CONCLUSIONS: Lacosamide
was shown to be a cost-effective adjunctive treatment in patients with uncon-
trolled partial-onset epilepsy in the United States.
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THRESHOLDS AND OUTCOMES: EVIDENCE FROM THE USE OF GLATIRAMER
ACETATE
Oleen-Burkey M1, Castelli-Haley J1, Dor A2, Lage M3
1Teva Pharmaceuticals, Kansas City, MO, USA, 2George Washington University, Washington,
DC, USA, 3HealthMetrics Outcomes Research, Groton, CT, USA
OBJECTIVES: Examinehowchanges in themedication possession ratio (MPR) affect
patient outcomes among multiple sclerosis (MS) patients treated with glatiramer
acetate (GA; Copaxone®). METHODS: Data were obtained from i3 InVision Data
Mart for january 1, 2006 – March 31, 2010. Patients were included if they were
diagnosed with MS, initiated therapy with GA, and had continuous insurance cov-
erage from 6 months prior through 24 months post initial use of GA (N839).
Multivariate regressions which controlled for patient characteristics examined the
association between achievement of alternative MPR goals and patient relapses
and charges. Logistic regressions were used to examine the relapses, while gene-
ralized linear models were used to examine charges. RESULTS: Patients who
achieved an MPR of at least 0.7 had significantly lower odds of relapse, with
achievement of a threshold of 0.7, 0.8 or 0.9, respectively, associated with an odds
ratio of relapse of 0.545 (95% CI 0.351 – 0.824), 0.530 (95% CI 0.371 – 0.870), and 0.421
(95% CI 0.260 – 0.679). Larger reductions in total direct medical charges, excluding
drugs, were seenwith higherMPR thresholds, For example, achievement of anMPR
threshold of at least 0.5 was associated with $1524 lower total charges (P0.0034),
while a MPR threshold of 0.90 was associated with $1825 lower charges (P0.0005).
Examining MS-related total charges, exclusive of drugs, revealed that a MPR
threshold of 0.90 was associated with $986 lower total MS-related charges
(P0.0498). Results also found an association between patient adherence to GA and
statistically significant reduction in inpatient, ER, outpatient, MS-related inpatient
and MS-related outpatient charges. CONCLUSIONS: As adherence improves the
odds of relapse decreases and cost-savings, exclusive of drugs, generally increase.
Results suggest that, despite the higher costs associated with increased usage of
GA, patient outcomes are improved and there are cost-offsets associated with
“compliant” use of the medication.
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OBJECTIVES:Huntington’s disease (HD) is a rare neurodegenerative disease affect-
ingmotor, cognitive and psychological function. Data collection is difficult because
of the low prevalence and the small number of specialized centers. The creation of
a specific self-administered questionnaire covering various clinical aspects of the
disease would make the HD-patient clinical data collection easier. Such an instru-
ment also offers the advantage of allowing a remote follow-up and getting infor-
mation on the development of motor, functional and behavioral disorders of HD
patients perceived by the patient himself. The objective of this study is to validate
a new self-reported clinical instrument for HD-patients.METHODS: The European
HD burden study (Euro-HDB) is an ongoing cross-sectional survey among HD-pa-
tients and their caregivers in six European countries. The H-CSRI, a self-reported
instrument based on the Unified Huntington’s Disease Rating Scale (UHDRS) and
developedwith the expertise of a neurologist and a psychiatrist, was administered.
It included three subscales assessing themotor, functional and behavioural ability.
Classical test theory and item response theory were used to assess its clinimetric
properties. RESULTS: Among 311 patients from both Italy and France, item re-
sponse rates range from 86% to 99%. There was a floor effect on items related to
psychotic disorder in the behavioral subscale, because these symptoms do not
affect all patients. The H-CSRI showed an acceptable reliability (Cronbach’s al-
phas 0.74). Factor analyses demonstrated a satisfactory construct validity. More-
over, the item internal consistency and item discriminant validity criteria were
met. The differential item functioning analyses showed no item bias between the
two countries and between genders. CONCLUSIONS: These data support the valid-
ity of the H-CSRI to assess the health status for patients with HD. Planned next
steps include assessments of responsiveness to change, test–retest reliability and
convergence between UHDRS and H-CSRI scales.
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OBJECTIVES:Migraine in some patients may be progressive, with increasing head-
ache day frequency leading to Chronic Migraine (CM). The relationship between
headache-days per month (HDPM) and health utility, a measure of health-related
quality of life (HRQoL), among patients with migraine has not been examined.
METHODS: The PREEMPT trials studied 1,384 patients with CM treated with
BOTOX® or placebo. The PREEMPT trials included migraine specific measures.
Noo instrument to directly capture health utility, however, was included. There-
fore, a validated mapping algorithm using patient characteristics, the Migraine
Specific Questionnaire v.2 (MSQ), and the EuroQol-5D (EQ-5D, UK weighted) was
applied to the PREEMPT dataset in order to estimate mean health utility by
health state, defined as 0-3, 4-9, 10-14, 15-19, 20-23, or24 HDPM. Analyses were
performed both regardless of treatment and stratified by treatment arm. Health
utility is a standard scale to measure HRQoL, ranging from 1, representing per-
fect health, to 0, representing death. RESULTS: PREEMPT patients were predom-
inantly female (86%) and Caucasian (90%), with amean age of 41. At week 24, mean
health utility for each of the HDPM categorieswas 0.75 (0-3 HDPM), 0.68 (4-9 HDPM),
0.62 (10-14 HDPM), 0.53 (15-19 HDPM), 0.53 (20-23 HDPM), and 0.52 (24 HDPM). A
similar trend of decreasing utility with increasing HDPMwas observed at baseline,
week 12, and week 56 and when stratified by treatment arm. CONCLUSIONS: An
inverse relationship is seen between health utility and HDPM, with the headache
frequency categories comprising CM (15-19, 20-23, and 24HDPM) associated with
the lowest HRQoL. Health utility defined by HDPM categories will be valuable for
estimating HRQoL gains as a result ofmigraine treatmentswhich aim to reduce the
number of HDPM among those suffering from migraine.
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OBJECTIVES: Chronic migraine is an undertreated and debilitating disease associ-
ated with significant morbidity. This research seeks to define meaningful health
states based on published literature and where necessary, expert opinion. Health
states defined by the number of headache-days per month (28 days; HDPM) expe-
rienced by patients with chronic migraine (15 headache days per month) can be
used to calculate transition probabilities that may be applied to cost-effectiveness
modeling. METHODS: Published literature, headache treatment guidelines,
heath utility, and health resource utilization, as well as the baseline distribution
of HDPM in the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Ther-
apy (PREEMPT) clinical trial program were considered to ascertain relevant HDPM
to define migraine health states. Subsequently, pooled trial data were used to
estimate transitions between health states per 12-week treatment cycle for pa-
tients treated with BOTOX® or placebo. Up to 24 weeks of double-blind data is
available from the PREEMPT phase 3 trials, with an additional 32 weeks of open-
label data for BOTOX® treated patients. All available data from the PREEMPT trials
were used to model transitions. A Bayesian approach with a Dirichlet distribution
was used to perform sensitivity analyses of these health state transitions.
RESULTS: We specified 6 unique health states, defined by number of HDPM: 0-3,
4-9, 10-14, 15-19, 20-23, and 24. The pooled trial cohort of 1384 patients (857 with
prior prophylaxis failure) were examined at baseline, week 12 and week 24 to
produce transition probabilities for both all patients and those with prior prophy-
lactic failure. Estimated transition probabilities modeled to one year time horizon
produce distributions that closely replicate the 56-week distribution of the PRE-
EMPT trial population. CONCLUSIONS: This research generated unique migraine
health states to form the foundation of cost-effectiveness models evaluating mi-
graine therapies.
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OBJECTIVES: Migraine is a debilitating disease with significant morbidity. This
research estimates the health resource utilization and associated cost of adult
Scottish migraneurs within 6 distinct health states, defined by number of head-
ache-days per month (28 days; HDPM), ranging from zero to 28, to inform a cost-
effectiveness analysis of prophylaxis of headache in patients with chronic mi-
graine (15 HDPM). METHODS: Standard cost of illness methods were used to
combine unit costs for physician office visits, inpatient and emergency room en-
counters for migraine, and triptan medication use. Resource utilization data was
taken from the International Burden of Migraine Study. Costs were derived from
the NHS 2008/09 reference costs for England, and from the Personal Social Services
Research Unit (PSSRU) costs. Total costs for each health state were estimated over
a three month time interval. RESULTS: Resource utilization increased across all
categories as the number of HDPM increased. Costs per 3 months ranged from
£35.05 for the 0-3 headache-days health state to £226.14 for the 15 HDPM
health state. The largest cost driver among the 15 HDPM was hospitalization
for migraine, which accounted for 52% of costs in 15 HDPM health state.
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